【drug-news】【资讯翻译】诺华提出新的试验数据证明Lucentis药物的安全性

http://www.reuters.com/article/2012/09/05/us-novartis-idUSBRE88409420120905
认领翻译的战友请跟帖注明“认领本文翻译，48小时内未完成，请其他战友认领！
请根据自己专业背景选择认领，如使用翻译软件翻译，被发现者扣分1-2分
请根据自己的专业背景选择相应的资讯认领，经常认领而不能及时提供优质稿件者将被列入黑名单，取消认领资格，请大家注意！
新近参与本次活动的会员请查看： http://news.dxy.cn/bbs/topic/21537141
寻找最近的翻译贴请查看： http://search.dxy.cn/?words=%E8%B5%84%E8%AE%AF%E7%BF%BB%E8%AF%91&bid=116&t=1&c=1&age=7&bid=116&limit=30&o=1
翻译时请参照版规 【版务】科技动态版版规及加分细则（ 2014-02-21 更新）
希望参与动态版其他活动的会员请查看版面右边栏的置顶部分。
Switzterland's Novartis said on Wednesday new data for Lucentis demonstrated the long-term efficacy and safety of the drug and also showed its benefits in treating a new condition, which Novartis will seek approval for.

Novartis said the new data reinforced the safety profile of Lucentis, an important drug for the firm with annualized sales of more than $2 billion, in wet age-related macular degeneration (AMD).

It said data also showed Lucentis helped patients with visual impairment due to choroidal neovascularization (CNV) secondary to pathological myopia (PM).

"Novartis will submit for regulatory approval in this indication in the European Union in the third quarter of this year and in Japan by the end of 2012," it said in a statement.